Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy

Inclusion Criteria:

• Unilateral/bilateral, upper/lower limb spasticity associated with cerebral palsy.

• Naïve to OnabotulinumtoxinA treatment and who, according to medical and to thestandard clinical practice criteria, will receive OnabotulinumtoxinA.

• Treated only with stable doses of short-acting muscle relaxants can be included inthe study, at the investigator's discretion, for at least 30 days prior to treatmentstarting, under the concept that at the time the steady state of the drug (stableplasma concentrations) will theoretically have been reached.

• Under adjuvant treatment with orthoses and other orthopedic devices can be includedin the study.

• Participants with physio/physical therapy can be included.

Exclusion Criteria:

• Previously treated with botulinum toxin for spasticity related to cerebral palsy.

• Diagnosed with Eaton-Lambert syndrome, myasthenia gravis, or other neurologicaldiseases with compromised neuromuscular transmission.

• History of hypersensitivity to the study drug or to any of the excipients in theformulation.

• Evidence of inflammation or infection in the anatomical region selected by theinvestigator for the study drug administration.

• Participants under treatment with drugs that interfere with neuromusculartransmission which, at the investigator's discretion, contraindicateOnabotulinumtoxinA concomitant administration.

• Have had orthopedic surgery in the segment to be infiltrated in the 12 months priorto drug application.